

Web-only References

1. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. *Arch Mal Coeur Vaiss* 1966; **59**: 263-272.
2. Dessertenne F. Un chapitre nouveau d'electrocardiographie: les variations progressives de l'amplitude de l'electrocardiogramme. *Actual Cardiol Angiol Int* 1966; **15**: 241-258.)
3. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the elctrocardiogram *Circulation* 1952; **6**: 378-388.
4. Sarma JSM, Sarma RJ, Bilitch M, Katz D, Song SL. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in human: reevaluation of Bazett's formula. *Am J Cardiol* 1984; **54**: 103-108.
5. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier J-M, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarisation during exercise in humans. *Circulation* 1991; **83**: 536-545.
6. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes. *Circulation* 1992; **86**: 1376-1382.
7. Seizer A, Wray HW. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. *Circulation* 1964; **30**: 17-26.
8. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndrome: A critical review, new clinical observations and a unifying hypothesis. *Prog Cardiovasc Dis* 1988; **31**: 115-172.
9. Lazzara R. Antiarrhythmic drugs and torsades de pointes. *Eur Heart J* 1993; **14**: H88-92.
10. Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF. *PACE* 1992; **15**: 551(abstr).
11. Amiodarone Trials Meta-analysis. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. *Lancet* 1997; **350**: 1417-1424.

12. <http://www.fda.gov/cder/foi/label/2001/21151s3lbl.PDF>
13. http://www.fda.gov/ohrms/dockets/ac/00/slides/3619s1_06_throckmorton.ppt
14. Stambler BS, Wood M, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT and the Ibutilide Repeat Dose Study Investigators. *Circulation* 1996; **94**: 1613-1621.
15. Houltz B, Darpo B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. *Pacing Clin Electrophysiol* 1998; **21(5)**: 1044-1057.
16. Corey AE, Al-khalidi H, Brezovic C, Marcello S, Parekh N, Taylor K, Karam R. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. *Clin Pharmacol Ther* 1997; **61**: 205.
17. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. *J Cardiovasc Pharmacol* 1993; **22**: 810-818.
18. Simons FER, Kesselmann MS, Giddings NG, Pelech AN, Simons KJ. Astemizole-induced torsades de pointes. *Lancet* 1988; **45**: 624.
19. Roy ML, Dumaine R, Brown AM. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. *Circulation* 1996; **94**: 817-823.
20. Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarisation in idiopathic long QT syndrome. *Am J Cardiol* 1987; **59**: 168-169.
21. Guelon D, Bedock B, Chartier C, Harberer J. QT prolongation and recurrent torsades de pointes during erythromycin lactobionate infusion. *Am J Cardiol* 1986; **58**: 666.
22. Lee KL, Jim M-H, Tang SC, Tai Y-T. QT prolongation and torsades de pointes associated with clarithromycin. *Am J Med* 1998; **104**: 395-396.
23. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. *Am J Kid Dis* 1997; **30**: 437-439.

24. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarisation in rabbit Purkinje fibres. *Fundam Clin Pharmacol* 1998; **12**: 70-76.
25. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ. Cardiac effects of antimalarial treatment with halofantrine. *Lancet* 1993; **341**: 1054-1056.
26. Sukontason K, Karbwang J, Rimchala W, Tin T, Na-Bangchang K, Banmairuroi V, Bunnag D. Plasma quinine concentrations in falciparum malaria with acute renal failure. *Trp Med Int Health* 1996; **1**: 236-242.
27. Matson PA, Luby SP, Redd SC, Rolka HR, Meriwether RA. Cardiac effects of standard-dose halofantrine therapy. *Am J Trop Med Hyg* 1996; **54(3)**: 229-231.
28. Touze JE, Bernard J, Keundjian A, Imbert P, Viguier, Chaudet H, Doury JC. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. *Am J trop Med Hyg* 1996; **54(3)**: 225-228.
29. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. *Eur J Clin Pharmacol* 1993; **45**: 191-193.
30. Honig PK, Wortham DC, Zamani K, Conner DP, Mulin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. *JAMA* 1993; **269**: 1513-1518.
31. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Locatis D, Bloch A. Torsades de pointes after treatment with terfenadine and ketoconazole. *Eur Heart J* 1992; **13**: 1002-1003.
32. Thorstrand C. Clinical features in poisoning by tricyclic antidepressants with special reference to the ECG. *Acta Med Scan* 1976; **199**: 337-344.
33. Claghorn JL, Schroeder J, Goldstein BJ. Comparison of the electrocardiographic effect of dothiepin and amitriptyline. *J Can Psychiatry* 1984; **45**: 291-291.

34. Baker B, Dorian P, Sandor P, Shapiro C, Mitchell J, Irvine MJ. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorders. *J Clin Psychopharmacol* 1997; **17**: 15-21.
35. Riddle MA, Nelson JC, Kleinman CS, Rasmussen A, Leckman JF, King RA, Cohen DJ. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. *J Am Acad Child Adolesc Psychiatry* 1991; **30**: 104-108.
36. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. *J Am Acad Child Adolesc Psychiatry* 1993; **32**: 792-797.
37. Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. *J Forensic Sci* 1997; **42**: 335-339.
38. Alderton HR. Tricyclic medication in children and the QT interval: case report and discussion. *Can J Psychiatry* 1995; **40**: 325-329.
39. Rouleau F, Asfar P, Boulet S, Dube L, Dupuis JM, Alquier P, Victor J. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. *J Cardiovasc Electrophysiol* 2001; **12**: 61-65.
40. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. *N Engl J Med* 2002; **346(20)**: 1591-1592.
41. Witton K. Phenothiazines and sudden death. *JAMA* 1965; **194**: 679.
42. Hulisz DT, Dasa SL, Black LD, Heiselman DE. Complete heart block and torsades de pointes associated with thioridazine poisoning. *Pharmacotherapy* 1994; **14**: 239-245.
43. Denvir MA, Sood A, Dow R, Brady AJ, Rankin AC. Thioridazine, diarrhoea and torsades de pointes. *J R Soc Med* 1998; **91**: 145-147.
44. Liberatore MA, Robinson DS. Torsades de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? *J Clin Psychopharmacol* 1984; **4**: 143-146.

45. Kriwisky M, Perry GY, Tarchisky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. *Chest* 1990; **98**: 482-484.
46. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsades de pointes. Successful therapy with isoproterenol. *JAMA* 1983; **249**: 2931-4.
47. Hale AS. A review of the safety and tolerability of sertindole. *Int Clin Psychopharmacol* 1998; **13(3)**: S65-70.
48. Sertindole NDA 20-644. Rockville, Md, Food and Drug Administration, Psychopharmacological Drugs Advisory Committee, 1996.
49. Barnett AA, Safety concerns over antipsychotics drug, sertindole. *Lancet* 1996; **348**: 256.
50. CSM/MCA. Suspension of availability of sertindole (serdolect). *Current Problems in Pharmacovigilance* 1999; **25**: 1.
51. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. *Am J Psychiatry* 1987; **144**: 673-675.
52. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. *Am J Med Sci* 1995; **309(6)**: 315-6.
53. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). *Clin Pharmacol Ther* 1999; **65(1)**: 10-20.
54. CSM/MCA. Cisapride (Prepulsid) withdrawn. *Current Problems in Pharmacovigilance* 2000; **26**: 1-2.
55. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. *Circulation* 1998; **20**: 204-210.
56. Coumel P. Safety of bepridil: from review of the European data. *Am J Cardiol* 1992; **69**: 75D-78D.

57. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. *JAMA* 1993; **270**: 2590-2597.
58. CSM/MCA. Terodiline. *Current Problems in Pharmacovigilance* 1991; **32**: 1.
59. Jones SE, Ogura T, Shuba LM, McDonald TF. Inhibition of the rapid component of the delayed-rectifier K⁺ current by therapeutic concentrations of the antispasmodic agent terodiline. *Br J Pharmacol* 1998; **125**: 1138-1143.
60. Ahnve S. QT interval prolongation in acute myocardial infarction. *Eur Heart J* 1985; **6**: D85-95.
61. Gottlieb SS, Cines M, Marshall J. Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure. *Pharmacotherapy* 1997; **17**: 830-831.
62. Martin AB, Garson A Jr, Perry JC. Prolonged QT interval in hypertrophic and dilated cardiomyopathy. *Am Heart J* 1994; **127**: 64-70.
63. Ramamurthy S, Talwar KK, Goswami KC, Shrivastava S, Chopra P, Broor S, Malhotra A. Clinical profile of proven idiopathic myocarditis. *Int J Cardiol* 1993; **41**: 225-232.
64. Ichida F, Fatica NS, O'Loughlin JE, Snyder MS, Ehlers KH, Engle MA. Correlation of electrocardiographic and echocardiographic changes in Kawasaki syndrome. *Am Heart J* 1988; **116**: 812-819.
65. Akiyama T, Batchelder J, Worsman J, Moses HW, Jedlinski M. Hypocalcemic torsades de pointes. *J Electrocardiol* 1989; **22**: 89-92.
66. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features; observation in 32 patients. *J Am Coll Cardiol* 1983; **2**: 806-817.
67. Curry P, Fitchett D, Stubb W, Krikler D. Ventricular arrhythmias and hypokalaemia. *Lancet* 1976; **2**: 231-233.
68. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. *Circulation* 1983; **68**: 846-856.

69. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, Matsuhisa M, Shimomura K. Bradycardia-induced abnormal QT prolongation in patients with complete heart block with torsades de pointes. *Am J Cardiol* 1992; **69**: 628-633.
70. Surawicz B. Electrophysiologic substrate of torsades de pointes: dispersion of repolarisation or early afterdepolarisation. *J Am Coll Cardiol* 1989; **14**: 172-184.
71. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsades de pointes with d,l-sotalol. *Circulation* 1996; **94**: 2534-2541.
- Ebert SN, Liu XK, Woosley RL. Female gender as a risk for drug-induced cardiac arrhythmias: evaluation of clinical experimental evidence. *J Womens Health* 1998; **7**: 547-557.